Calidi Biotherapeutics Inc (CLDI)
Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on immuno-oncology in the United States. The company is developing allogeneic stem cell-based and enveloped virus platforms designed to support the delivery of oncolytic viruses. Its pipeline includes CLD-101, which is being studied in Phase 1b/2 and Phase 1 dose-escalation trials for high-grade glioma and recurrent high-grade glioma, respectively. Other programs include CLD-201 for several solid tumors, CLD-301 for multiple indications, and CLD-400 for certain lung cancer and metastatic solid tumors. Calidi also works with virus platforms under names such as NeuroNova, SuperNova, and RTNova. The company was founded in 2014 and is based in San Diego, California. The listed security is common stock on the NYSE.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-CLDI
|
$0.17
|
76.3% Upside
|
Bargain
|
$120 121,362.3% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-0.1x
|
0.5x
|
—
|
2.25 M
|
-2.124 M
|
50.1%
|
97.6%
|
-56.3
|
—
|
73.6%
|
